Anti-HIV Agent
AssigneeFuso Pharmaceutical Industries, Ltd.
InventorsNobutaka Wakamiya, Katsuki Ohtani, Takashi Sakamoto, Hiroyuki Keshi, Yuichiro Kishi
Life of this patent
Estimating the term…
Abstract
Disclosed are anti-HIV agents which comprise a mannose binding protein (MBP) as an active component and are useful for effectively inhibiting progress of diseases state in and useful in therapy for individuals infected with human immunodeficiency virus (HIV). Also disclosed are a method for evaluating an anti-HIV activity of MBP comprising the step of culturing HIV infected cells under the presence of MBP.
Claims23
1-17. (canceled)
A method for evaluating an anti-HIV activity of MBP, comprising:
- (a) culturing HIV infected cells prepared by putting target cells under the presence of HIV;
- (b) preparing clean cells by washing the infected cells;
- (c) culturing the clean cells under the presence of MBP;
- and
- (d) determining p24 protein from HIV in the culture supernatant.
19-21. (canceled)
25-27. (canceled)
39-40. (canceled)
A method for evaluating an anti-HIV activity of MBP, comprising:
- culturing HIV-infected cells in a cell culture medium, in the presence of mannose binding protein (MBP);
- and
- evaluating anti-HIV activity of the MBP by measuring HIV virus in the culture supernatant, wherein anti-HIV activity of MBP is indicated by reduction in the measurable HIV virus in the culture supernatant, compared to a control culture.
Dependencies are inferred from the claim text.